Compare Canadian Natural Resources Ltd. (CNQ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian Natural Resources Ltd. vs Novo Nordisk A/S — how do they compare? Canadian Natural Resources Ltd. trades at $47.64 (market cap $98.11B), while Novo Nordisk A/S trades at $46.39 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.1× Canadian Natural Resources Ltd.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| CNQ | NVO | |
|---|---|---|
Market Cap | $98.11B | $207.85B |
Sector | Energy | Health |
52-Week High | $50.55 | $63.98 |
52-Week Low | $29.31 | $35.29 |
Enterprise Value | $108.54B | $222.55B |
Dividend Yield | 3.73% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canadian Natural Resources (CNQ) trades at $47.65, up 0.85% with strong technical momentum. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $1.53 versus $1.43 expected, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 11.82 and EV/EBITDA of 6.35, while profitability metrics impress with 26.69% ROE and 22.87% net margin. Recent news highlights record production and dividend consistency.
CNQ presents a compelling investment case with strong operational performance, attractive valuation, and shareholder returns through dividends. The primary risks include oil price volatility and execution challenges in capital projects. Analyst consensus remains strongly bullish with 27 buy ratings and no sell recommendations, supporting upside potential from current levels.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
